JUMP TO CONTENT
Blue and white pills

Understanding INDs and NDAs in Clinical Research

Posting date: 22/04/2025
Author: Inside ICON

What is an IND or NDA? A Guide for Aspiring Clinical Research Professionals

If you’re considering a career in clinical research or the broader pharmaceutical and biotech industry, you’ve likely come across terms like IND and NDA. But what do these acronyms really mean, and why are they so important in drug development?

Whether you're exploring jobs in clinical operations, regulatory affairs, or research coordination, understanding the lifecycle of a new drug—and the regulatory milestones it must pass—is essential. In this blog, we'll walk you through the IND (Investigational New Drug application) and NDA (New Drug Application), how they differ, and what they mean for professionals working in clinical trials.

What is an IND?

IND stands for Investigational New Drug application. It’s the very first regulatory green light a sponsor must secure before beginning clinical trials in humans.

Pharmaceutical companies or research sponsors must submit an IND to regulatory authorities - like the FDA (U.S. Food and Drug Administration) in the United States, when they want to move a new compound from the preclinical (i.e. lab and animal testing) phase to clinical trials in humans.

It’s a formal request that essentially says: “We’ve done the necessary lab work and testing. Now, we want to test this drug in humans - and here’s all the data we have to support that request.”

What's included in an IND Application?

An IND is more than just a form. It includes a comprehensive package of documents and data, such as: 

  • Preclinical study results (including pharmacology and toxicology data) 
  • Manufacturing information about the drug compound 
  • Clinical trial protocols describing how the study will be run 
  • Investigator brochures that explain the investigational product to clinical researchers 
  • Informed Consent Forms (ICFs) to ensure participants are aware of the risks 

The IND must demonstrate that the drug is reasonably safe for initial human testing, typically starting with a Phase I clinical trial.

What happens after an IND is submitted?

Once an IND is submitted, the FDA has 30 days to review it. If the agency doesn’t raise objections, the sponsor may proceed with human testing.

It’s worth noting that INDs can be commercial (for future marketing approval) or research/investigator-sponsored (for academic or institutional studies).

This is where Clinical Research Associates (CRAs), Clinical Trial Managers (CTMs), and Regulatory Affairs professionals start to get involved in monitoring, managing, and ensuring compliance throughout the study process.

From IND to NDA 

After the IND is approved and the investigational drug has progressed through Phases I, II, and III of clinical trials (which can take several years), the sponsor may then file an NDA—the New Drug Application.

Think of the NDA as the formal request to bring the drug to market. If the IND was the “please let us test this,” the NDA is the “please let us sell this.”

What is an NDA?

The New Drug Application (NDA) is submitted to the FDA to demonstrate that a new pharmaceutical product is safe and effective for its intended use. 

The application includes: 

  • Data from all phases of clinical trials 
  • Information on drug formulation and manufacturing 
  • Details on labeling, dosage, and instructions for healthcare providers 
  • A risk-benefit analysis for regulators to assess 

In other global markets, the equivalent process may involve other authorities like the EMA (European Medicines Agency) in Europe or PMDA in Japan. While the terminology may differ (e.g. a Marketing Authorisation Application (MAA) in the EU), the fundamental concept is similar.

IND vs NDA - Key Differences

Aspect                      IND (Investigational New Drug)                 NDA (New Drug Application) 

Purpose                    Request to start clinical trials                    Request to market/sell the drug 

Submission              Before Phase I trials begin                        After successful completion of Phase III

Submitted To           FDA (or other national authorities)            FDA (or other national authorities)

Focus                        Safety for testing in humans                     Efficacy and safety for public use

Includes                   Preclinical data, trial protocols                  Full clinical trial data, labeling info

Challenges with IND & NDA Submissions 

Both INDs and NDAs are subject to intense scrutiny, and the regulatory pathway is rarely smooth sailing. Challenges include: 

  • Data quality and integrity: Any inconsistencies in clinical data can delay approvals. 
  • Timelines: Preparing submission documents can take months, and reviews may involve back-and-forth with regulators. 
  • Compliance: Regulatory requirements change frequently and vary by region. 
  • Collaboration: Successful submissions require close coordination across clinical, regulatory, medical writing, and quality assurance teams. 

For those working in or pursuing careers in clinical research, it’s helpful to develop cross-functional awareness - understanding not just your immediate responsibilities, but how they contribute to the broader picture.

Career Advice

If you're searching for jobs in clinical trials, clinical operations, or regulatory affairs, knowing the difference between an IND and NDA helps you: 

  • Understand where a project sits in the drug development pipeline 
  • Speak confidently about the trial lifecycle in interviews 
  • Identify the kind of experience you're gaining in a role 
  • Determine what kind of sponsor or study phase you'd prefer to work on 

For example, if you're working on Phase I trials, you're operating under the scope of an IND. If you're supporting submission readiness, you're likely contributing to an NDA. 

This knowledge also helps when planning your career path. For example, professionals working in regulatory writing, clinical data management, or pharmacovigilance all play roles during different stages of these submissions.

Career Opportunities

If you’re entering the world of clinical research, here are a few roles where IND and NDA knowledge can be especially valuable: 

  • Regulatory Affairs Associate/Manager Helps prepare submissions and interacts with regulatory agencies. 
  • Medical Writer Drafts the clinical study reports and summaries included in applications. 
  • Clinical Project Manager Oversees trial execution, ensuring milestones for IND or NDA readiness are met. 
  • Clinical Research Associate (CRA) Monitors trial conduct and site compliance, ensuring data meets submission standards. 
  • Quality Assurance Specialist Audits trial documentation and systems to ensure regulatory compliance. 

Understanding INDs and NDAs can also open doors to drug safety, compliance, or CMC (chemistry, manufacturing, and controls) roles.

Closing Thoughts

INDs and NDAs are fundamental checkpoints in the journey of turning an idea in a lab into a life-saving medicine. For professionals in the clinical research and pharmaceutical industry, they’re also key touchpoints that shape roles, responsibilities, and even career paths. 

Whether you're applying for your first clinical research job or planning your next move, understanding these terms can give you a clearer picture of where your work fits into the big picture.

If you're interested in a career in the Clinical Research industry, view our current openings at ICON today.
List #1

Related jobs at ICON

Lead Clinical Data Science Programmer

Salary

Location

Mexico

Department

Biometrics Roles

Location

Mexico

Business Area

ICON Strategic Solutions

Job Categories

Biometrics Portfolio

Job Type

Permanent

Description

As a Lead Clinical Data Science Programmer  you will be joining the world’s largest & most comprehensive clinical research organisation, powered by healthcare intelligence. You will have the opportuni

Reference

2025-119038

Expiry date

01/01/0001

Magda Obregon

Author

Magda Obregon
Read more Shortlist Save this role
Pathologist

Salary

Location

US, Farmingdale, NY

Department

Full Service - Development & Commercialisation Solutions

Location

New York

Remote Working

Office Based

Business Area

ICON Full Service & Corporate Support

Job Categories

Laboratory

Job Type

Permanent

Description

At ICON, it’s our people that set us apart. Our diverse teams enable us to become a better partner to our customers and help us to fulfil our mission to advance and improve patients’ lives.Our ‘Own It

Reference

JR130959

Expiry date

01/01/0001

Hanna Pitcairn Read more Shortlist Save this role
Global Study Administrator

Salary

Location

London, Poland, Spain

Department

Clinical Operations Roles

Location

Poland

Spain

London

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Clinical Trial Support

Job Type

Permanent

Description

ICON plc is a world-leading healthcare intelligence and clinical research organization. We’re proud to foster an inclusive environment driving innovation and excellence, and we welcome you to join us

Reference

2025-119620

Expiry date

01/01/0001

Tanzina Guerni Read more Shortlist Save this role
Project Analyst I - Language Services

Salary

Location

Mexico, Mexico City

Department

Full Service - Development & Commercialisation Solutions

Location

Sao Paulo

Santiago

Bogota

Mexico City

Lima

Remote Working

Hybrid: Office/Remote

Business Area

ICON Full Service & Corporate Support

Job Categories

Project/ Program Management

Job Type

Permanent

Description

As a Project Analyst in the Language Services department at ICON, you will support the management of translation projects for pharmaceutical and clinical clients. You will support with project coordin

Reference

JR128865

Expiry date

01/01/0001

Florencia  Borello Taiana Read more Shortlist Save this role
View all
List #1

Related stories

Silver ribbon
Recognising World Schizophrenia Day through Research and Compassion

Teaser label

Industry

Content type

Blogs

Publish date

05/22/2025

Summary

World Schizophrenia Awareness Day 2025 Every year on 24 May, World Schizophrenia Awareness Day offers a vital opportunity to raise awareness, dismantle stigma, and celebrate the strength of individ

Teaser label

Explore how ICON is advancing schizophrenia research and addressing stigma through clinical innovation.

Read more
Ovarian cancer knot being held in woman's hands
Standing Strong on Ovarian Cancer Day

Teaser label

Inside ICON

Content type

Blogs

Publish date

05/08/2025

Summary

Standing Strong on Ovarian Cancer Day:    ICON's Commitment to Advancing Care Ovarian cancer remains one of the most challenging gynaecologic malignancies, both in terms of detection and treatmen

Teaser label

Martin Lachs, VP, Oncology Project Management at ICON discusses ICON’s role in advancing ovarian cancer research.

Read more
Nurse and patient
Patient Centricity in Clinical Research

Teaser label

Industry

Content type

Blogs

Publish date

05/07/2025

Summary

Patient Centricity in Clinical Research: What it is and Why it Matters In the past, clinical research was designed around the needs of sponsors, researchers, and regulatory bodies. Patients were of

Teaser label

Discover how patient centricity is reshaping clinical research by placing participants at the heart of study design and execution.

Read more
View all
List #1

Recently viewed jobs

View Jobs

Browse popular job categories below or search all jobs above